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1
 SUMMARY 
 The neuregulins are a subset of the ligands for the epidermal growth factor receptor family 
of receptors. They can bind to these receptors and evoke a range of cellular responses. Some of 
the neuregulins have however been found in the cell nucleus associated with nucleoli and intra-
chromatin granules. This brief review summarises the data for nuclear expression obtained from 
observations on normal and malignant tissues and the various laboratory experiments conducted to 
explore the system. Finally, we discuss the possible functions that could result from intra-nuclear 
expression of these molecules. 
 Key Words :  Neuregulin ;  Heregulin ;  NRG ;  Growth factor ;  Growth factor receptor ;  Breast 
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 1. INTRODUCTION 
 Cells need to both send and receive signals that instruct them or their neighbours in an 
organised tissue when to grow and to divide. One system involved in these processes is the 
peptide growth factors and their receptors, which possess ligand-regulated tyrosine kinase 
activity. A subclass of these is the epidermal growth factor (EGF) family of four receptors 
and their 11 ligands. In the conventional signalling pathway membrane bound or secreted 
ligands interact with the extracellular domain of the appropriate growth factor receptor(s) on 
the plasma cell membrane, causing receptor dimerisation (and oligomerisation), thereby 
inducing increased receptor phosphorylation and transducing signals to the nucleus (and 
other sites such as the cytoskeleton) via a cascade of second messengers. This results in 
transcription factors mediating altered gene expression leading to many diverse events 
including differentiation, proliferation, cell migration, or apoptosis. 
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 There is now, however, much evidence that some of the ligands are present unexpectedly 
within the nucleus of cells in tissues. This evidence involves not just the members of the EGF 
family of related ligands but many others from a variety of signalling systems. Perhaps the 
best studied are the fibroblast growth factors (FGFs), which have been extensively investi-
gated by Olsnes and coworkers for many years. Excellent reviews covering this large body 
of work have appeared  (1– 3) . Other molecules from different families with growth regulatory 
activity reported in the nucleus are platelet derived growth factor  (4) , interferon  g , vascular 
endothelial growth factor, parathyroid hormone-related protein, prolactin, growth hormone 
 (5, 6) , hepatoma growth factor and several of the cytokines  (1) . 
 All proteins are synthesised on ribosomes and so originate in the cytoplasm. Some leave 
this compartment by exocytosis and are released into the interstitial space as soluble proteins 
while others are membrane incorporated molecules, which, following transport to the plasma 
cell membrane, can be released by regulated proteolytic cleavage  (7) . When these released 
ligands bind to receptors at the cell surface they may be internalised, and in some cases escape 
the alternatives of degradation or recycling to the cell exterior by exiting from these pathways 
and gaining access to the cytoplasm. The pathway undertaken by the FGFs involves receptor 
binding and internalisation in endosomes but, as these become acidified, the ligands appar-
ently unfold and traverse the endosomal membrane reaching the cytoplasmic compartment 
 (1, 2) . Others synthesised in the cytoplasm may simply remain there. The two alternatives are 
therefore very distinct and involve quite different systems and interactions. 
 This review concerns the intranuclear localisation of (at least) one of the splice variants 
of the  NRG1 gene and some less extensive observations on the  NRG2 ,  3 and  4 gene products. 
The EGF family consists of the four receptors (EGFR/HER1/ErbB1, HER2/ErbB2, HER3/
ErbB3 and HER4/ErbB4) and the 11 known ligands (EGF, TGF alpha, heparin binding-EGF, 
Amphiregulin, Betacellulin, Epiregulin, Epigen and the four NRG genes). Several of these 
ligands have been reported to be found, on occasions, inside the nucleus including EGF itself 
 (3) , Betacellulin  (8) and both the human Amphiregulin protein  (9) and its rat equivalent 
called Schwannoma derived growth factor  (10, 11) . Presumably these are not directly associ-
ated with the inner leaflet of the nuclear envelope as they contain no transmembrane or signal 
sequences. They could be bound to membrane-associated proteins or be present complexed 
with intranuclear protein ensembles such as nucleoli and the variety of, to date rather poorly 
molecularly characterised, systems such as splicosomes, and various intranuclear entities 
such as PML bodies (see  https://npd.hgu.mrc.ac.uk/index.html for the Nuclear Protein 
Database) or, finally, they may be genuinely soluble in the nucleoplasm. 
 2. OBSERVATIONS ON NRG IN THE NUCLEUS 
 The neuregulins are ligands for the HER3/ErbB3 and HER4/ErbB4 receptors, which, when 
present extracellularly, may bind to these receptors and elicit a number of intracellular activities 
 (12) . Four members of the family have so far been identified definitively: these are NRG 1, 
2, 3 and 4. Other candidate ligands such a Neuroglycan C  (13) or the Tomoregulins  (14) have 
not, as yet, been studied in great detail and more data on their behaviour is required before 
they can be accepted as bona fide members of the NRG family. NRGs 1–4 are signalling 
proteins involved in many organ systems in normal tissues including the breast, heart and 
nervous system. Each gene produces multiple splice variants of a considerable variety of 
structures (for NRG 1 reviewed by 12) and for NRG 2, 3 and 4  (7) . Signalling by NRGs leads 
to cell responses including migration, differentiation, stimulation or inhibition of proliferation, 
apoptosis and adhesion. Neuregulins are also expressed in many forms of cancer including 
breast, colon, head and neck, lung, ovarian, skin and prostate  (15) . 
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 Some of the neuregulins have been found in cell nuclei. The first observation reported in 
the literature was that radioactively labelled NRG1, when administered to cultured breast 
cancer cells, was taken up and shown to accumulate within the nucleus where it was reported 
to promote induction of expression and nuclear translocation of the proto-oncogene  c-myc (16) . 
Other evidence supporting this finding has since accumulated using immunohistochemical 
staining. The neuregulin precursor was shown to localise to the nucleus in papillary thyroid 
carcinoma but not in normal thyroid tissue  (17) . Human endometrial stromal cells have been 
shown to occasionally display staining in the nucleus with antibodies against NRG1 a and  b 
 (8) . Immunohistochemical staining of DCIS of the breast showed rather dramatic nuclear expres-
sion of NRG1 a , NRG1 b and NRG3 in 40–50% of the cases examined  (18) (Fig. 1a). It should 
be noted, however, that immunohistochemical staining of invasive breast cancers using the 
same antibodies for NRG1 a and  b , NRG2 a and  b , NRG3 and NRG4 gave no evidence of 
nuclear staining  (19) . An antibody specific to the A1 isoform of NRG4 showed intense staining 
of the nucleus in rat salivary gland tissue  (20) but NRG4 did not show nuclear staining in 
prostate cancer cases studied  (20) . Clearly these results are fragmentary and a systematic 
study of the subcellular localisation of the main isoforms of the products of the four NRG 
genes should be undertaken in both normal and malignant human tissue to fully catalogue the 
incidence of intranuclear expression. Not only will this complete the data but it may stimulate 
hypotheses as to why some tissue types show intranuclear expression and others do not. 
 3. NRG EXPERIMENTS 
 While observations of NRGs in the nucleus have been made in normal and malignant 
tissues what experimental evidence is available to confirm these observations? And does any 
of this information give insight into why NRGs are found in the nucleus and what possible 
consequences might this have in diseases such as breast cancer? This information may be of 
some practical value as soluble NRG1 has, for instance, been shown to be associated with 
breast cancer progression  (21) and is a key promoter of breast cancer tumorigenicity and 
metastasis independently of erbB-2 overexpression  (22) . Indeed blocking the expression of 
NRG1 suppresses the aggressive phenotype of a breast cancer cell line and in vivo reduces 
tumour formation, size and halts metastasis  (22) . 
 NRG1 b 3 one of at least 15 different isoforms of NRG1, which lacks a transmembrane 
domain, is not secreted from the cell but has a putative nuclear localization sequence (NLS) 
at its N-terminus  (23) . Immunohistochemical staining in DCIS of the breast using antibodies 
specific for NRG1 b showed nuclear localisation  (18) but this technique cannot resolve which 
structures in the nucleus NRG1 could be co-localising to. Digital fluorescent microscopy has 
higher resolution and, in addition, experiments can be performed with mutated or truncated 
NRG forms. NRG1 b 3 tagged with GFP (either at the C or N terminus) was transfected into 
a variety of cell types (including fibroblasts or epithelial cells and using cells from human, 
monkey, rodents or dog) and the localisation of the expression of the protein was visualised 
using low-light wide-field or confocal digital microscopy. When expressed in each of these 
cell types this isoform showed localisation to nucleoli alone, localisation to SC35-positive 
nuclear speckles alone or a combination of both patterns in one cell  (23) (Fig.  1b ). 
 Two lines of evidence demonstrate that this localisation is receptor-independent  (23) . 
NRG1 b 3 localisation using NR6 cells, which lack all the EGFR family receptors, was indis-
tinguishable from other cell types and second, deletion of the EGF domain had no effect on 
nucleolar or SC35 spliceosome localisation  (23) . The observation of two patterns was 
resolved by filming individual cell nuclei where the patterns could be seen to interconvert 
over a period of about 90 min. It is not yet known if this occurs at a particular phase of the 
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 Fig. 1.  ( a ) Immunohistochemical staining of invasive breast adenocarcinoma treated with a 
NRG1 b antibody displaying strong, nuclear staining in the epithelial cells (hp × 400). ( b ) 
The distribution of NRG1 b 3-GFP within the nucleus of African green monkey kidney 
(Cos7) cells using low-light digital microscopy. These pictures show three different patterns 
of distribution that occur: (1) nucleoli localisation, (2) localisation to SC35-positive speckles 
and (3) an intermediate pattern containing speckles and nucleoli. 
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cell cycle nor if the NRG molecules move from one location to the other (or are degraded 
and resynthesised) but experiments are underway to answer these issues. Deletion analysis 
by Golding et al.  (23) and by Breuleux et al.  (24) showed that the N-terminal 21 amino acids 
of NRG1 b 3 were required for intranuclear accumulation and localisation to nucleoli and that 
residues within the IgG domain (which lies N-terminal to the EGF motif) are required for 
localisation to spliceosomes. 
 4. NRG FUNCTIONS IN THE NUCLEUS 
 Two basic alternative mechanisms of action (if any occurs) in the nucleus can be hypoth-
esised, receptor-mediated and non-receptor mediated (clearly these are not exclusive). 
While it has been shown that nuclear localisation does not require the presence of a member 
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of the EGF receptor family, nor the presence of an EGF domain in the NRG, this does not 
resolve the issue as to whether a receptor-mediated function could occur once the molecule 
has reached the nucleus. 
 The evidence for members of the EGF family of growth factor  receptors in the nucleus 
mostly comes from the use of directly labelled proteins (using reporters such as radioactive 
isotopes or GFP tagging) or indirectly by the use of antibodies for immunogold labelling and 
electron microscopy, immunofluorescence and immunostaining. These latter methods are 
progressively less precise in their ability to reliably determine subcellular localisation. Immuno-
staining cannot (at least in most hands) conclusively differentiate between peri-nuclear and 
genuine nuclear localisation. On the other hand immunogold labelling is known to be subject 
to occasional artifactual positive results and is rarely accepted on its own as sufficient proof 
of nuclear expression. Immunofluorescence can also be prone to error unless carefully per-
formed and controlled. 
 In a recent review by Bryant and Stow  (3) the authors discuss ‘the continuing conundrum’ 
of the assumption of full length transmembrane growth factor receptors ‘moving out of 
membranes and existing as matrix-associated proteins in cell nuclei’. The authors readily 
acknowledge that this ‘remains a prickly concept’. Many would agree when considering a 
typical transmembrane growth factor receptor such as the EGFR, which has about 500 amino 
acids ‘extracellular’ that are folded into a highly organised structure, stabilised with 25 
disulphide bonds and decorated with about 60 KDa of complex sugars. In this hypothesis it 
is assumed that this structure unfolds, the disulphide bonds break and the (essentially) linear 
sequence of the protein, presumably together with the 11 or so complex carbohydrate chains, 
cross the membrane of (for instance) an intracellular vesicle. Then the protein refolds (in its 
glycosylated form) and its 25 disulphide bonds all reform in the correct arrangement in the 
cytoplasm (which is a non-oxidising environment due to the ratio of glutathione and reduced 
glutathione)  (25) such that it can resume its cellular functions as a soluble protein. Currently 
there is no evidence that this can occur for any transmembrane protein, and thermodynamic 
as well as many other considerations make the possibility remote. 
 An alternative hypothesis is that growth factor receptors are indeed found associated with 
nuclei but in the nuclear membrane, not in a full-length soluble form in the nucleoplasm. 
Evidence in support of this concept includes that receptors will be synthesised by nuclear 
membrane associated ribosomes (as the nuclear membrane is contiguous with the ER). 
The nuclear membrane is not a simple balloon surrounding the nucleus but has multiple 
intranuclear invaginations and pores  (26) . Thus nascent receptors will be found in the outer 
leaflet of the nuclear envelope, and in any intranuclear invaginations of this, but it is arguable 
if these are functional as they are yet to be glycosylated, a fate which awaits them in the 
Golgi apparatus. Of course, it has been well known that growth factor receptors, after ligand 
activation, migrate in vesicles to the peri-nuclear tubulovesicular membrane structures where 
they are easily seen using experiments such as GFP tagging. Whether these can fuse with 
membranes contiguous with the nuclear membrane remains a possibility. 
 How could the view that intranucleoplasmic localisation of full-length growth factor 
receptors occurs have arisen? A typical (non-polarised) cultured cell is remarkably flat with 
an aspect ratio often exceeding 10:1 (similar to a dinner plate). Thus, in such a flat cell the 
nucleus is much like the ham in a sandwich of (from the top) plasma membrane, endoplas-
mic reticulum, various vesicular structures and then the double nuclear membrane (with 
nuclear invaginations) and the same set of membranes present in the reverse order below the 
nucleoplasmic compartment. In each of these membrane layers growth factor receptors will 
be found according to current thinking regarding their site of synthesis and subsequent 
movements and destinations. It is not surprising that using wide-field microscopy, and even 
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perhaps confocal microscopy, that distinguishing the ham from the sandwich requires rather 
careful experiments. 
 The exception to this is the HER4/ErbB4 receptor, which is subject to regulated proteolysis, 
which results in a soluble intracellular fragment that clearly does traffic to the nucleus and 
enters the nucleoplasm  (27) . In this case, however, the fragment lacks all of the ligand binding 
sites and could not interact with, nor be activated by a neuregulin ligand. Thus, it is perhaps 
best to view the issue of genuinely nucleoplasmic, full-length, soluble growth factor receptors 
as open. Finally, it has been very recently reported that addition of an inhibitor of the EGF 
receptor, Gefitinib, causes alterations in the intranuclear location of NRG1 but this drug is 
now known to inhibit up to 37 kinases  (28) and to have further off-target effects so whether 
this is indicative of the involvement of the specific receptors, other kinases or simply a 
response to cell stress remains to be shown  (29) . 
 If there are no relevant members of the EGF receptor family in the nucleus what could 
NRG1 be doing there? The only clues come from the sub-nuclear localisation to nucleoli and 
to interchromatin granules. Even more intriguing is the apparent transition from one location 
to another, although it is yet to be shown that the molecules move rather than being degraded 
and re-synthesised. Several proteins share this behaviour of being sequestered in the nucleolus 
and then being released, notably Cdc14, which is a cell cycle regulator  (30) . Thus, this will 
be important to determine if the nuclear NRG is released and re-localises, and whether this is 
associated with a particular phase of the cell cycle. Possible functions in these sub-compartments 
are regulating ribosome synthesis and pre-mRNA splicing. Some evidence for an involvement 
in the latter comes from the use of a yeast two hybrid system and co-immunoprecipitation 
where interactions with nuclear proteins involved in transcriptional control were detected 
 (24) . The receptor-mediated effects of NRGs are to stimulate quiescent cells to enter the cell 
cycle, and to decrease the time of the cycle, thereby increasing cell numbers. In parallel the 
cell has to increase its rate of molecular synthesis, an event linked to the number (and effi-
ciency) of ribosomes. It is not inconceivable that NRG may have a dual role in promoting 
transit through the cell cycle and cell growth but this is currently speculation. Experimental 
approaches to the problem may be based on ‘candidate’ effects such as the level of ribosomal 
RNA or splicing efficiency or discovery approaches such as transcriptomics or proteomics. 
 When first observed, perhaps mainly because it did not fit with current paradigms of cellular 
signalling, nuclear growth factors were considered an artefact. With the large body of obser-
vations and experiments this now seems unlikely. The main unresolved question remains 
what are the functions of these molecules in this compartment. When this is determined 
much of the other aspects of the system may fall into place. 
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